NASDAQ: OTLKOutlook Therapeutics Inc Stock
$0.63+0.01 (+1.61%)
Updated Sep 29, 2026
OTLK Price
$0.63
Fair Value Price
-$0.14
Market Cap
$152.40M
52 Week Low
$0.16
52 Week High
$2.54
P/E
-0.81x
P/B
-14.66x
P/S
-186.84x
PEG
N/A
Dividend Yield
N/A
Revenue
-$1.16M
Earnings
-$61.12M
Gross Margin
195.6%
Operating Margin
5,364.4%
Profit Margin
5,253.5%
Debt to Equity
-3.52
Operating Cash Flow
-$56M
Beta
1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
OTLK Overview
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OTLK's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
OTLK
Ranked#276 of 466
Ranked#276 of 466
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.78 | A | |
| $8.05 | A | |
| $365.27 | A |
Be the first to know about important OTLK news, forecast changes, insider trades & much more!
OTLK News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OTLK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OTLK ($0.63) is overvalued by 547.92% relative to our estimate of its Fair Value price of -$0.14 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
OTLK ($0.63) is not significantly undervalued (547.92%) relative to our estimate of its Fair Value price of -$0.14 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
OTLK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more OTLK due diligence checks available for Premium users.
Valuation
OTLK fair value
Fair Value of OTLK stock based on Discounted Cash Flow (DCF)
Price
$0.63
Fair Value
-$0.14
Undervalued by
550.79%
OTLK ($0.63) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
OTLK ($0.63) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
OTLK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OTLK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.81x
Industry
9.98x
Market
47.86x
OTLK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-14.66x
Industry
5.25x
OTLK's financial health
Profit margin
Revenue
$8.7k
Net Income
-$20.3M
Profit Margin
-233,554.9%
OTLK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
OTLK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$26.2M
Liabilities
$36.6M
Debt to equity
-3.52
OTLK's short-term liabilities ($28.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OTLK's short-term assets ($23.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OTLK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
OTLK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$21.0M
Investing
$0.0
Financing
$26.6M
OTLK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OTLK vs Biotech Stocks
Outlook Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.